Zepbound vs Wegovy Cost (2026): Self-Pay, Insurance Copay, Caremark Formulary & Total-Cost Comparison

Zepbound and Wegovy are the two FDA-approved weight-loss-indicated GLP-1 injections in 2026. The cash-pay landscape is closer than it's ever been: Wegovy NovoCare self-pay $349/month standard pen vs Zepbound LillyDirect self-pay $299/$399/$449/month by strength. With insurance + manufacturer copay savings card both can drop to $25/month. But the CVS Caremark July 2025 formulary swap made Wegovy the preferred step on most commercial Aetna and CVS Caremark formularies until October 1, 2026, when Caremark added Zepbound back as an additional preferred option — so the practical insurance cost still depends on which formulary your plan uses. Plus SURMOUNT-5 (NEJM 2025) showed tirzepatide produces ~22% mean weight loss vs ~14% for semaglutide, so the per-pound-lost cost analysis differs from the raw monthly comparison. Below: the head-to-head cost decision.

The short answer

• Cheapest cash-pay Wegovy: $349/month at NovoCare self-pay (standard pen, all doses 0.25-2.4 mg; $199 for a new patient's first two months)
• Cheapest cash-pay Zepbound: $299/month at LillyDirect Zepbound self-pay program (2.5 mg vial only). Other vial strengths: $399 (5 mg) or $449 (7.5-15 mg). Telehealth memberships that sell the brand drugs, such as altRx, list Zepbound and Wegovy well above these manufacturer self-pay prices.
• Same price with insurance: as little as $25/month for either drug with manufacturer copay savings card on commercially-insured plans
• BUT check your formulary: the CVS Caremark July 2025 swap removed Zepbound from most commercial formularies in favor of Wegovy as the preferred step, and on October 1, 2026 Caremark added Zepbound back as an additional preferred option. On Caremark plans that adopted the change and cover weight-loss drugs, both are preferred again; a plan that kept a custom Wegovy-only formulary may still deny Zepbound.
• Per-pound-lost cost is closer. SURMOUNT-5 (NEJM 2025) showed tirzepatide ~22% weight loss vs semaglutide ~14% — so even at higher per-month cost, Zepbound delivers more weight loss per dollar in the published head-to-head.

Cash-pay side-by-side (as of July 2026)

The CVS Caremark formulary swap: July 2025 exclusion, October 2026 return

From July 2025 through September 2026, on most commercial Aetna and CVS Caremark-managed formularies, Wegovy was the single preferred step, and Zepbound required the Aetna 6981-A P04-2025 Exception process. The affected formulary codes per the verbatim Aetna 6981-A bulletin are ACCF, ACF, ACFC, SCCF, SF, SFC, VF, VFC . Effective October 1, 2026, CVS Caremark added Zepbound back to its commercial formularies as an additional preferred option, for plan sponsors that elect to cover weight-loss drugs.^[6] Plan sponsors can still customize their formulary, so the exception step may survive on some plans.

Practical implications for the cost comparison:

• If your Caremark plan adopted the October 2026 change: Zepbound and Wegovy are both preferred options, so the choice comes down to efficacy, tolerability, and your copay tier.
• If your plan still runs a Wegovy-only Caremark formulary on one of those codes: Wegovy will likely approve cleanly at the standard copay tier ($25/month with savings card). Zepbound requires the 6981-A exception process, which adds delay and is denied for many patients without a documented Wegovy intolerance or failure.
• If your plan is NOT on a Caremark formulary (e.g., some Cigna plans, some BCBS plans): Both drugs typically approve under the same generic GLP-1 weight-management criteria.
• Cash-pay path is unaffected by formulary. NovoCare self-pay $349/month Wegovy and LillyDirect $299-$449/month Zepbound are available regardless of insurance. If you can't get Zepbound through insurance, the LillyDirect path is the workaround.

For the full Aetna PA criteria including 6981-A and 6947-C, see our Aetna PA guide. For the Cigna IP0814 (Wegovy) and IP0816 (Zepbound) weight-management criteria (no Caremark-style preferred-step swap), see our Cigna PA guide. For the practical mechanics of switching between Wegovy and Zepbound after a formulary swap — the verbatim §2 dose ladders, the SURMOUNT-5 head-to-head trial that anchors any re-titration conversation, and the side-effect reset to expect on the new drug — see our Wegovy ↔ Zepbound switch dose-equivalence guide.

Per-pound-lost cost analysis

Raw monthly cost comparison is close: Wegovy is $349 at every standard dose, while Zepbound runs $299-$449 at LillyDirect rates, so Wegovy is cheaper at maintenance doses. But the SURMOUNT-5 (NEJM 2025) head-to-head showed tirzepatide produces materially more weight loss than semaglutide. If your goal is weight loss per dollar, the math changes: For the cash-pay side of that comparison across every dose, see the TrumpRx GLP-1 price table.

Caveats on the per-pound math:

• The cost-per-pound calculations assume sustained therapy for 18 months — most weight loss happens in the first year, with maintenance dosing thereafter
• Trial weight loss is a population mean; individual response varies
• Discontinuation produces ~2/3 regain at 1 year per the STEP-1 extension (Diabetes Obes Metab 2022, PMID 35315183) — which means the “cost-per-pound” is really the cost-per-pound-while-you-keep-taking-it. See our Life After GLP-1 maintenance hub for the long-term maintenance considerations.
• Insurance-covered access at $25/month copay makes both drugs nearly equivalent in cost — the choice then comes down to formulary access, side-effect tolerance, and efficacy preference rather than dollars

HSA / FSA eligibility

Brand-name Wegovy and Zepbound are generally HSA/FSA eligible as a medical expense with a valid prescription per IRS Publication 502. This applies to NovoCare and LillyDirect cash-pay purchases as well as insurance-copay payments. The manufacturer copay savings cards CAN sometimes be combined with HSA/FSA payment — verify with your plan administrator. Compounded semaglutide / tirzepatide from licensed 503A pharmacies are typically also HSA/FSA eligible with a prescription, though some plan administrators require a Letter of Medical Necessity. Our list of HSA/FSA-eligible tirzepatide providers covers telehealth clinics that say you can pay with HSA or FSA funds. If you want brand and compounded options from one prescriber, RxSpan MD lists Wegovy and Zepbound next to its compounded plans. For the prescription itself, see how to get Zepbound online or how to get Wegovy online.

Decision framework: which costs less for you?

• You have commercial insurance with both drugs on formulary, no Caremark preferred-step issue: Either is $25/month with copay savings card. Choose based on efficacy preference (Zepbound) or familiarity with semaglutide (Wegovy).
• You have commercial insurance on a CVS Caremark-managed formulary that still uses the Wegovy-only 6981-A exception codes: Wegovy will approve easily; Zepbound requires exception process. Default to Wegovy unless you have a documented intolerance. Since October 1, 2026, Caremark's commercial formularies list Zepbound as an additional preferred option, so confirm whether your plan adopted that change first.
• You're cash-pay and want the cheapest monthly: NovoCare $199/month for a new patient's first two Wegovy fills, then $349/month, OR LillyDirect $299/month Zepbound 2.5 mg vial (the starting dose). Wegovy if you want to escalate without dose-tier price changes.
• You're cash-pay and want maximum weight loss for the dollar: Zepbound at LillyDirect $449/month (7.5-15 mg vials) — costs ~50% more per month than NovoCare Wegovy but delivers ~40% more weight loss per the SURMOUNT-5 head-to-head.
• You want the cheapest brand-name oral option: Wegovy oral pill 1.5/4 mg at NovoCare $149/month OR Foundayo (orforglipron, oral GLP-1) at $149/month — both are oral, both are $149/mo. Foundayo is a different molecule (not semaglutide).
• You're Medicare-eligible: Wegovy and Zepbound (KwikPen only) become available on Medicare Part D Bridge starting 07/01/2026 at $50/month flat copay for eligible MA-PD members (BMI ≥27 + heart disease or prediabetes). Bridge runs through 12/31/2027.

For the broader landscape of every Wegovy alternative beyond just the Zepbound switch — including the new Foundayo (orforglipron) oral GLP-1, Saxenda + the Teva generic (August 2025), the compounded semaglutide cash-pay path with regulatory caveats, and the non-GLP-1 options (Qsymia, Contrave, Xenical/alli) — see our Wegovy alternatives 2026 complete guide.

Further reading

• Wegovy vs Zepbound matchup
• SURMOUNT-5 trial deep-dive (tirzepatide vs semaglutide head-to-head)
• Top tirzepatide weight-loss studies (curated PubMed reading list)